Hybridoma cell lines producing antibodies to RSV NS1

This technology provides a new set of hybridoma cell lines each expressing a single monoclonal antibody against human respiratory syncytial virus (RSV) nonstructural protein 1 (NS1). These antibodies have variously been shown to detect NS1 protein in an enzyme-linked immunosorbent assay (ELISA), Western blot assay, immunofluorescence microscopy of paraformaldehyde-fixed cells, and flow cytometry. The various antibodies can vary in their efficiency in each of these assays. This technology provides a unique set of qualified monoclonal antibodies against RSV NS1 protein which currently do not exist. These antibodies and cell lines may be of interest to any persons investigating RSV infection processes, particularly as it relates to the activity of NS1 in such an infection process.This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration.NIAIDE-167-2018-0Ease of manufactureUnique research toolViral diagnosticsVaccine research3339Jan 25, 2021Monday, January 25, 2021NIAIDNIAIDNIAIDhttp://irp.nih.gov/pi/peter-collinsPeterSoukas5601 Fishers Lane, Suite 6D (MSC 9804)[e-mail] Office of Technology Transfer240-627-3117Infectious DiseasesDiagnosticsViralNon-AIDS (only)VaccinesResearch MaterialsRM Catalog - reviewed and deemed appropriate for RM CatalogOtherInfectious DiseasesInfectious Dise...

Source: NIH OTT Licensing Opportunities - January 25, 2021 Category: Research Authors: ott-admin Source Type: research